Xintela receives Notice of Allowance from USPTO for quality assurance of chondrocyte-based productsLund, Sweden, July 29, 2020 - Xintela today announces that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the company's patent application covering quality assurance of chondrocytes (XACT), which is important for the development of chondrocyte-based cell therapy products. This Notice of Allowance means that the USPTO intends to grant the patent after certain formal steps have been completed. Once granted, the patent will be valid until 2038. Xintela's US patent application no. 16/387,172 protects the use of the company's cell surface markers - integrin 101 and integrin 111 - for the development and quality assurance of chondrocytes used for regeneration of cartilage tissue in the treatment of cartilage damage.
"We are very pleased with this intention to grant which shows how we continue to innovate to broaden the use of our integrin markers and in this case for the development and quality assurance of high quality chondrocyte products. The patent further validates our marker technology platform in cell therapy and has great value in discussions with potential collaboration partners and licensees for the important US market", says Xintela's CEO Evy Lundgren-Åkerlund.
Xintela has previously reported on the company's analytical method for chondrocytes, XACT (Xintela Assay for Cell Therapy), which makes it possible to determine the quality and purity of chondrocyte preparations and also to actively select high-quality chondrocytes best suited for repair of damaged cartilage. Xintela has previously validated this technology in collaborations with companies that develop chondrocyte-based cell therapies.
This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the below contact, for publication on the 29th of July 2020.
Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: [email protected]
Medicon Village
223 81 Lund, Sweden
www.xintela.se
About Xintela
Xintela is an Advanced Therapy company developing regenerative cell therapies and targeted cancer therapies based on the patented marker technology platform XINMARK®. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to isolate and quality assure stem cells for the treatment of musculoskeletal diseases including osteoarthritis (OA). Studies on horses with OA have demonstrated that the stem cells are safe and that they have a positive effect on cartilage and bone. Xintela has established an in-house GMP-facility for manufacturing of stem cells and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, [email protected].
The following documents can be retrieved from beQuoted
2020-07-29-patent-godkannande-XACT-USA-eng.pdf
If you want to open the text in your webbrowser
click here
______________________________________________________
This information was sent by beQuoted
If you want more information, please go to www.beQuoted.com
To change your subscription, please inform [email protected] beQuoted Press är en service till Dig som är intresserad av finansiell information. Med beQuoted Press underlättas företagens finansiella kommunikation till Dig och till nyhetsbyråer, aktieägare, placeringsrådgivare och andra intressenter på aktiemarknaden.
Vi hoppas att Du uppskattar denna service.
| 